ACTRIMS 2022 | Recent progress and future needs in NMOSD treatment

Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Boston, MA, describes the substantial progress made in the treatment of neuromyelitis optica spectrum disorder (NMOSD) in recent years. Eculizumab, satralizumab, and inebilizumab have all been approved by the FDA since 2019 and through their varying mechanisms of action, they provide valuable options for different scenarios. Head-to-head comparisons are still needed. Dr Levy also comments on the lack of new options to treat acute relapses and the strategies under investigation to tackle this. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.